SUPRIYA vs THEMISMED: Stock Comparison
SUPRIYA LIFESCIENCE is the larger company by market capitalisation. SUPRIYA LIFESCIENCE shows a higher ROE, faster revenue growth and lower leverage, while THEMIS MEDICARE shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SUPRIYA leads 8; THEMISMED leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SUPRIYA | THEMISMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | SUPRIYA | THEMISMED |
|---|---|---|
| Live Price | ₹861.4 | ₹98.8 |
| Day Change | -0.91% | 1.31% |
| Volume | 37,872 | 12,634 |
| 52-Week High | ₹1,085 | ₹140.6 |
| 52-Week Low | ₹545.5 | ₹64.95 |
| Distance from 52W High | -20.61% | -29.73% |
Valuation
| Metric | SUPRIYA | THEMISMED |
|---|---|---|
| Market Cap | ₹6,950 Cr | ₹889 Cr |
| P/E Ratio | 35.11x | 22.24x |
| P/B Ratio | 5.82x | 2.23x |
| EPS | ₹2.99 | ₹2.67 |
| Book Value | ₹148.82 | ₹43.28 |
| Dividend Yield | 0.12% | 0.52% |
Growth
| Metric | SUPRIYA | THEMISMED |
|---|---|---|
| Revenue Growth (TTM YoY) | 50.2% | 6.7% |
| EPS Growth (TTM YoY) | 46.7% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | SUPRIYA | THEMISMED |
|---|---|---|
| ROE | 17.46% | 0.29% |
| ROCE | 19.21% | -0.27% |
| Net Margin | 25.26% | 0.33% |
| Operating Margin | 33.42% | -0.42% |
| Debt to Equity | 0x | 0.25x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SUPRIYA | THEMISMED |
|---|---|---|
| Promoter Holding | 68.3% | 57.5% |
| FII Holding | 6.44%▲ 0.25 pp | 0.01% |
| DII Holding | 5.47%▲ 0.17 pp | 0.01% |
| Public Holding | 19.79%▼ 0.42 pp | 32.87% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUPRIYA LIFESCIENCE and THEMIS MEDICARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.